Maxigen Biotech Inc. (TPE:1783)

Revenue by Product

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Biomedical	698.34M
Biomedical Growth	8.34%
Adjustments and Reversals	-17.69M
Adjustments and Reversals Growth	-58.73%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Taiwan	298.86M
Taiwan Growth	8.43%
United States	196.57M
United States Growth	-1.13%
Asia	75.12M
Asia Growth	-21.60%
Europe	58.98M
Europe Growth	111.19%
Other	51.13M
Other Growth	113.59%